,
2 min read
China remains one of the most attractive pharmaceutical markets globally, making the China drug approval process a critical focus for innovators, generic manufacturers, and biotech companies. However, navigating the National Medical Products Administration (NMPA) framework requires a clear understanding of evolving pathways, technical requirements, and post-approval obligations. To help simplify market entry, here are 13 frequently asked questions every company should know.
1. Who regulates drug approvals in China?
The National Medical Products Administration (NMPA) is China’s regulatory authority responsible for drug approvals, inspections, pharmacovigilance, and lifecycle compliance.
2. What medicinal products can be registered?
China regulates:
- Chemical drugs
- Biological products
- Traditional Chinese medicines
- Cosmetics
Each category follows different registration pathways.
3. What is the first step in the China drug approval process?
Most companies begin with:
- Product classification
- Regulatory gap assessment
- Submission pathway strategy
- Data readiness review
Early planning can significantly reduce delays.
4. Is local representation required?
Foreign applicants are required to have a local legal entity or authorized agent to support registration, communication, and compliance activities in China.
5. What dossier format does China use?
China follows the CTD/eCTD format, including:
- Module 1: Administrative information
- Module 2: Summaries
- Module 3: Quality data
- Module 4: Nonclinical data
- Module 5: Clinical data
6. Are clinical trials required in China?
Depending on the product type, existing overseas data, and pathway eligibility, local studies may be required, reduced, partially waived or waived.
7. Are accelerated approval pathways available?
Yes. China offers expedited mechanisms such as:
- Breakthrough Therapy Designation
- Conditional Approval
- Priority Review
- Special Review Pathways
8. Have timelines improved recently?
Yes. China continues to optimize review efficiency. NMPA announced a 30-working-day IND review pathway for eligible innovative drugs, helping speed clinical development.
9. Can overseas commercial batches be imported before approval?
No. However, to shorten the time between approval and market supply, China introduced provisions allowing eligible pre-approval commercial-scale batches of overseas-marketed drugs under defined conditions.
10. What is the MAH system?
Under China’s Marketing Authorization Holder (MAH) system, the authorization holder is accountable for product quality, safety, efficacy, and post-market compliance.
11. What happens after approval?
Companies must manage:
- Pharmacovigilance reporting
- Variations and renewals
- Labeling updates
- GMP compliance
- Post-market commitments
12. What causes delays?
Common reasons include:
- Incomplete dossiers
- Data inconsistencies
- Poor localization/translation
- Delayed query responses
- GMP readiness gaps
- QC test sample readness and import, testing
13. How can companies improve success rates?
Best practices include:
- Early regulatory strategy
- Strong technical documentation
- China-specific gap assessments
- Lifecycle planning
- Local regulatory expertise
How Freyr Solutions Can Help
Freyr Solutions supports companies with:
- China regulatory strategy
- NMPA registrations and submissions
- eCTD publishing
- MAH/local representation support
- Lifecycle management
- Pharmacovigilance compliance
Final Thoughts
The China drug approval process offers major commercial opportunities, but success depends on understanding evolving NMPA expectations and choosing the right pathway early. Planning to register your product in China? Connect with Freyr Solutions and speak with our China regulatory experts today.
